These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)]. Scheen AJ Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704 [TBL] [Abstract][Full Text] [Related]
25. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Langtry HD; Lamb HM Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318 [TBL] [Abstract][Full Text] [Related]
26. The fluoroquinolones after ciprofloxacin and ofloxacin. Hooper DC Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519 [No Abstract] [Full Text] [Related]
27. Levofloxacin, a second-generation fluoroquinolone. North DS; Fish DN; Redington JJ Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306 [TBL] [Abstract][Full Text] [Related]
28. Symposium on antimicrobial therapy. VII. The fluoroquinolones. Greenfield RA J Okla State Med Assoc; 1993 Apr; 86(4):166-74. PubMed ID: 8387106 [TBL] [Abstract][Full Text] [Related]
29. Levofloxacin and sparfloxacin: new quinolone antibiotics. Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794 [TBL] [Abstract][Full Text] [Related]
31. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Croom KF; Goa KL Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657 [TBL] [Abstract][Full Text] [Related]
33. The fluoroquinolones. Walker RC Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871 [TBL] [Abstract][Full Text] [Related]
34. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Martin SJ; Jung R; Garvin CG Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723 [TBL] [Abstract][Full Text] [Related]
35. The role of fluoroquinolones in tuberculosis today. Berning SE Drugs; 2001; 61(1):9-18. PubMed ID: 11217874 [TBL] [Abstract][Full Text] [Related]
36. Use of fluoroquinolones: practical considerations. Ponte CD; Fisher MA Am Fam Physician; 1993 Apr; 47(5):1243-9. PubMed ID: 8465719 [TBL] [Abstract][Full Text] [Related]
38. Fluoroquinolones: how to use (but not overuse) these antibiotics. Sable CA; Scheld WM Geriatrics; 1993 Jun; 48(6):41-4, 49-51. PubMed ID: 8500773 [TBL] [Abstract][Full Text] [Related]
39. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections. Fong IW Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054 [TBL] [Abstract][Full Text] [Related]
40. Developing drug use evaluation criteria for parenteral fluoroquinolones. Guay DR; Covington TR; Alexander VL Pharmacotherapy; 1993; 13(2 Pt 2):54S-57S. PubMed ID: 8474940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]